BIOSWITCH is the feasibility infrastructure for biomanufacturing. We help companies transitioning to bio-based production identify and validate the pathways worth building, before any strain engineering begins. No one builds a house without checking the foundation. No one should engineer a strain without checking BIOSWITCH first.
The transition from petrochemical to bio-based production is one of the most consequential industrial shifts of our time. Biomanufacturing offers a credible path to decarbonizing the production of specialty chemicals, food ingredients, pharmaceuticals, and materials — but only if companies can actually get there. Today, the 80% failure rate of bio-production projects doesn't just destroy shareholder value; it erodes confidence in bio-based transitions and slows the pace of decarbonization across entire industries. BIOSWITCH accelerates this transition by removing the feasibility barrier that kills most projects before they reach commercial scale. By helping companies identify viable bio-production pathways earlier and cheaper, we reduce the R&D waste associated with failed attempts, lower the financial risk of transitioning away from fossil-based inputs, and make bio-based production accessible to mid-market companies that cannot afford multi-million euro exploratory programs. At scale, the downstream impact is significant. Every viable bio-production pathway that reaches commercialization represents a chemical process that no longer depends on petrochemical feedstocks, a supply chain that becomes more resilient to geopolitical disruption, and a production system that can be powered by renewable carbon. BIOSWITCH is the infrastructure that makes more of these transitions possible — not by replacing the science, but by ensuring the right science gets resourced in the first place. Beyond environmental impact, accessible feasibility infrastructure has meaningful socioeconomic implications. Lowering the cost and time barrier to bio-production feasibility assessment opens the door for smaller companies, emerging market players, and mission-driven startups to compete in spaces previously dominated by large chemical conglomerates with deep R&D budgets.
80% of bio-production projects fail after companies spend €1–5M and 12–24 months on pathways that were never viable. The problem isn't the science — it's that economic and biological feasibility gets discovered too late, after significant capital and time have already been committed to the wrong direction.
BIOSWITCH is the feasibility infrastructure layer for biomanufacturing. We built the first end-to-end feasibility stack specifically designed for companies transitioning from chemical to bio-based production, helping them identify, filter, and validate biosynthetic pathways before any strain engineering begins.
The stack operates in four stages. First, computational pathway search enumerates all known and computed biosynthetic routes for a target molecule across a large metabolic model space including multiple organisms, ranked by an AI scoring system validated against expert-curated pathways. We are building the largest metabolic pathway atlas for biomanufacturing.
Second, early-stage techno-economic analysis and scientific metrics filters out non-viable routes before any lab work begins. This is our intelligence layer.
Third, biochemical validation tests the top pathway candidates using cell-free technology, confirming biological feasibility at throughput and in weeks rather than months.
Fourth, strain optimisation and whole-cell validation takes only the validated winners into engineering, compressing a traditionally 12–24 month process into 3–6 months.
The result: companies transitioning to bio-based production only invest in pathways that have already passed both scientific and economic scrutiny. Bad biomanufacturing pathways get killed early. Capital goes further.
Every bio-production project should start with a BIOSWITCH search.